Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Update

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 495,062 shares, an increase of 465.6% from the March 31st total of 87,521 shares. Currently, 0.1% of the company's stock are sold short. Based on an average daily trading volume, of 527,925 shares, the days-to-cover ratio is currently 0.9 days.Analyst Ratings ChangesSeparately, Citigroup downgraded Sysmex from a "strong-buy" rating to a "hold" rating in a report on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Sysmex has an average rating of "Hold".Check Out Our Latest Report on SysmexSysmex Price PerformanceSysmex stock traded up $0.13 during trading hours on Friday, hitting $8.71. 129,178 shares of the company traded hands, compared to its average volume of 200,974. Sysmex has a 1-year low of $8.15 and a 1-year high of $19.39. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12. The firm has a market cap of $5.48 billion, a P/E ratio of 18.15 and a beta of 1.13. The firm's 50-day simple moving average is $8.82 and its two-hundred day simple moving average is $9.74. Sysmex (OTCMKTS:SSMXY - Get Free Report) last released its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. The firm had revenue of $837.32 million for the quarter, compared to analyst estimates of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. As a group, analysts forecast that Sysmex will post 0.44 earnings per share for the current fiscal year. About Sysmex (Get Free Report)Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics. The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.See AlsoFive stocks we like better than SysmexThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Sysmex Right Now?Before you consider Sysmex, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here